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Abstract
Introduction:Recombinant Newcastle Disease virus (rNDV) vectored vaccines are
safe mucosal applicable vaccines with intrinsic immune-modulatory properties for
the induction of efficient immunity. Like all viral vectored vaccines repeated
inoculation via mucosal routes invariably results to immunity against viral vaccine
vectors. To obviate immunity against viral vaccine vectors and improve the ability
of rNDV vectored vaccines in inducing T cell immunity in murine air way we have
directed dendritic cell targeted HIV-1 gag protein (DEC-Gag) vaccine; for the
induction of helper CD4þ T cells to a Recombinant Newcastle disease virus
expressing codon optimized HIV-1 Gag P55 (rNDV-L-Gag) vaccine.
Methods: We do so through successive administration of anti-DEC205-gagP24
protein plus polyICLC (DEC-Gag) vaccine and rNDV-L-Gag. First strong gag
specific helper CD4þ T cells are induced in mice by selected targeting of anti-
DEC205-gagP24 protein vaccine to dendritic cells (DC) in situ together with
polyICLC as adjuvant. This targeting helped T cell immunity develop to a
subsequent rNDV-L-Gag vaccine and improved both systemic and mucosal gag
specific immunity.
Results: This sequential DEC-Gag vaccine prime followed by an rNDV-L-gag
boost results to improved viral vectored immunization inmurine airway, including
mobilization of protective CD8þ T cells to a pathogenic virus infection site.
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Conclusion: Thus, complementary prime boost vaccination, in which prime and
boost favor distinct types of T cell immunity, improves viral vectored
immunization, including mobilization of protective CD8þT cells to a pathogenic
virus infection site such as the murine airway.
Introduction
The high genetic variability of the human immunodeficiency
virus type 1 (HIV-1) and the tendency to persist in hidden
viral reservoir have seriously hampered the development of
safe and effective vaccines (reviewed in Ref. [1–5]). More so
Lifelong highly active anti-retroviral therapy (HAART) is
limited by the continuous emergence of drug resistance and
is not curative (reviewed in Ref. [6]). Since they can
selectively kill virus producing cells the induction of potent
HIV-1 specific T cell immunity as a component of
prophylactic or therapeutic vaccine remains a highly desired
objective ([7, 8] reviewed in Ref. [1]). The presence of robust
multifunctional T cell immunity for example has been
associated with long term viremia suppression of HIV-1 in
Elite controller ([9, 10], rev. in Ref. [11]) and has also been
implicated in preclinical studies in the control of pathogenic
Simian immunodeficiency virus infections [12, 13].
Viral vectors are the most efficient vaccine vectors and are
being actively optimized for immunization against infec-
tious diseases and cancers (rev. in Ref. [14]). Unfortunately
several clinical evaluation of viral vectored HIV-1 vaccines in
multiple heterologous prime boost combinations have
yielded limited success [15–18]. In addition to the poor
immunogenicity of some of these vaccine candidates a major
obstacle has been pre-existing or the risk of the induction of
anti-vector immunity during the course of immuniza-
tion [19, 20]. We previously reported that preprograming of
helper CD4þ T cells using dendritic cells targeted protein-
based vaccine enables DNA vaccines to be more immuno-
genic in mice [22]. One component of the improved
protection was a more rapid accumulation of gag-specific
CD8þT cells to amucosal infection challenge site. Previously
to improve viral vectored HIV-1 gag vaccine we targeted the
encoded antigen to dendritic cells in situ using either
adenoviral or rNDV vectored HIV-1 vaccine leading in
enhanced T cell immunity [21]. In this study we have
demonstrated that successive administration of anti-
DEC205-gagP24 protein plus polyICLC and rNDV-L-gag
vaccines results to vigorous systemic and mucosal T cell
immunity. Here antigen specific helper CD4þ T cells are
elicited by a priming dose of a DEC-targeted protein vaccine
which then improves the induction of T cell immunity by a
rNDV-L-gag vaccine. In addition to an enhanced T cell
immunity; this approach strongly amplified persistent CD8þ
T cells in murine airway and improved protection against
airway challenge with a recombinant vaccinia gag virus. To
the best of our knowledge, this is the first viral vectored—
dendritic cell targeted protein vaccine combination strategy
in mice in which the concept of helper CD4þ T cells has been
exploited not only to direct the induction of a balancedHIV-
1 gag specific T cell immunity but equally to intentionally
focus protective CD8þ T cell responses at the site of
pathogenic virus challenge. In contrast to our previous
findings on complementary prime boost vaccination where a
more rapid accumulation of gag-specific CD8þ T cells
occurred upon pathogenic virus challenge, here enhanced
accumulation of vaccine induced T cells to the lungs is
driven by mucosal rNDV-L-gag application.
We previously used the term ‘‘complementary’’ prime
boost to describe a DEC-gag prime plus DNA boost [22].
Here we extend this concept to include DEC-gag prime plus
rNDV-L-gag boost where an anti-DEC205-gagP24 plus
polyICLC protein vaccine is combined with viral vectored
vaccine to enhance protective T cell immunity in murine
airway.
Materials and Methods
Mice and rNDV-L-gag vaccination
CxB6 F1 mice from Harlan were maintained under
specific-pathogen free conditions and used at 6–10 weeks
under the guidance of the Rockefeller University Institu-
tional Animal Care and Use Committee. Mice were
inoculated with rNDV-L-gag or rNDV-L-GFP intranasally
as previously reported [21]. The mice were anesthetized
with Halothane. On the other hand DEC-gag plus
polyICLC injection was given subcutaneously in the
paws as previously reported [22, 23].
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Ethical statement
Mice weremaintained under specific-pathogen free conditions
and used at 6–10 weeks under the guidance of the Rockefeller
University Institutional Animal Care and Use Committee.
Cell lines, media, and antibodies
A 293 T (293ts/A1609), CHOneo cells, and CHOmDEC205
cell lines were maintained in DMEM supplemented with 5%
FCS, penicillin, streptomycin and glutamine. CV-1 cells were
maintained in this medium but with geneticin in place of
streptomycin. Antibodies to CD3, CD4, CD8a, and
cytokines (IFN-g, IL-2, and TNF-a) were purchased from
BD Biosciences-Pharmingen, San Jose, CA. Other anti-
bodies were from Beckman coulter including FITC labeled
(KC57-FITC; Coulter) or HRP-conjugated antibody (Im-
munoDiagnostics, Woburn, MA) to HIV gag p24 and HIV
gag CD8þ tetramer (AMQMLKETI) H-2Kd PE.
Fusion HIV-1 gag mAbs
These were generated as described [24, 25]. SDS/PAGE was
used to assess the quality of the anti-DEC-gagP24 (DEC-gag)
fusion proteins, while western blotting using HRP-anti-p24
(ImmunoDiagnostics) was used to determine the specificity
of the gag fusion constructs. mAb binding was verified on
CHO cells stably transfected with the mouse DEC-205 by
FACS, using either PE-conjugated goat anti-mouse IgG
(Jackson ImmunoResearch, West grove, PA) or FITC-
conjugated anti-p24 (KC57-FITC, coulter). All mAbs were
endotoxin-free in limulus Amebocyte Lysate assay, QCL-
1000 (Cambrex, Walkersville, MD).
15-mer peptide libraries
Overlapping (staggeredby 4 aa) 15-merpeptides spanning the
entire HIV-1 gag p24 [25] were synthesized by the proteomic
Resource Center (The Rockefeller University). The resuspen-
sion had previously been reported in [22, 23, 25].
Immunizations
Female CXB6 F1 mice were injected once subcutaneously as
described above with 5ug DEC-gag together with poly-ICLC
(50mg Oncovir, NW Washington, DC) as adjuvant. 4 wks
later the mice received either a boost with 1 106 rNDV-L-
gag i.n. or a second dose of 5ug DEC-gag plus 50 ug poly-
ICLC subcutaneously Polyinosinic–polycytidylic acid-poly-
lysine-carboxymethylcellulose (poly-ICLC, Hiltonol; Onco-
vir, Washington, DC, USA) is a stabilized double-stranded
RNA (dsRNA).
Assays for HIV-specific immune T cells
To determine the breadth of HIV-1 gag-specific T cell
responses, bulk splenocytes were restimulated in vitro either
with peptidesmix spanning the entire gagP24 protein [24, 25]
or a negative unreactive control peptide mix consisting of
HIV-1 nef pool mix in the presence of 2mg/ml of anti-CD28
(clone 37.51) for 6 h, adding 10ug/ml brefeldin A (Sigma–
Aldrich, St. Louis, MO) for the last 4 h to accumulate
intracellular cytokines. Dead cells were excluded using live/
dead fixable dead stain kit (Aqua live/dead; Invitrogen). After
blocking Fcg receptors, the cells were stained with antibodies
to CD3-pacific blue, CD4-percp, CD8-alexa-750, and Aqua
live/dead stain for 20min at 378C. Cells were washed, fixed
(Cytofix/cytoperm; BD Bioscience), permeabilized with
Permwash and stained with antibodies to IFNg (IFNg-
alexa-700), IL-2 (IL-2-FITC), and TNF-a (TNF-a-PE-CY7)
for 15min at room temperature. All antibodies were from
Ebioscience. We use BD LSRII for acquisition with data
analysis in Flowjo (Tree Star, Inc).
HIV-1 gag CD8þ tetramer staining
Lymphocytes were washed once with PBS and stained with
HIV-1 gag CD8 tetramer (AMQMLKETI) H-2Kd PE, CD3-
pacific blue, CD4-percp, CD8-alexa-700, and Aqua live/dead
for 20min at 48C as previously described [22, 24].
Vaccinia gag protection assays
Nembutal-anesthetized mice were challenged with 105 PFU/
mouse of infectious recombinant vaccinia gag virus by the
intranasal route, in 35ml PBS with Mg/Ca. The negative
controls were wild type vaccinia virus, Vaccinia-luciferase or
vaccinia-OVA virus. The weight of each animal (groups of 5)
was determined daily for 7 days following challenge. Then
mice were euthanized, the lungs were harvested and
homogenized in transport medium (0.1% gelatin in PBS),
and stored in duplicates at 808C prior to virus titration.
Lung virus titers of individual mice in each group were
determined by plaque assay on monolayers of CV-1 cells as
described [21–26].
CD8þ and CD4þ T cell depletion
Vaccinated animals were depleted of CD8þ T-cells, by
injection 150mg of anti-CD8 antibody (clone 2.43) at day2,
1, and 0 before challenge. In the depletion of CD4 T cells
200mg of anti-CD4antibody (cloneGK.1.5) similarly injected
during the same time interval. To deplete both CD4þ and
CD8þ T cells vaccinated mice were treated a combination of
100ug of each depletion antibody. A normal rat IgG (200mg
per mouse) was injected in a control group. The effectiveness
of the depletion was assessed at day 0 prior to the challenge
through staining for T cells in the lungs and spleen.
Statistics
Post challenge mean Vaccinia virus lung titers and mean
percentage in weight loss were compared between
L. N. Ngu et al. Complementary prime boost vaccination in mice
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vaccination groups using two tailed Student’s t test.
Differences were considered significant at p< 0.05 after
analysis using prism 6 Graph Pad Software. Similarly
differences in mean total tetramer binding CD8þ T cells
were also compared using two tailed student’s Test.
Results
Complementary prime boost vaccination with DC
targeted gag protein vaccine and rNDV-L-gag
enhances protective immunity to airway
challenge with vaccinia gag
We previously demonstrated that a complementary prime
boost with DC-targeted HIV-1 gag protein vaccine and DNA
enhances protective CD4þ/CD8þ T cell immunity to airway
challenge with a high dose of recombinant vaccinia gag
virus [22]. Here we extend this concept to include the
enhancement of protection afforded by combining a DC-
targeted gag protein vaccine prime and rNDV-L-gag boost.
To test the protection afforded by protein and rNDV-L-gag
vaccines, we first compared two doses of DC-targeted, DEC-
gag protein vaccine to two doses of rNDV-L-gag vaccine,
given 1month apart in a homologous prime boost approach,
and challenged 12 weeks later with a lethal intranasal dose of
recombinant vaccinia-gag virus. Weight loss was monitored
daily and at days 6–7, the mice were euthanized and lung
virus titers determined as previously described [22–25, 27].
Both protein and rNDV-L-gag forms of vaccine in a
homologous prime boost vaccination resulted to 2–2.5 log
fold less lung virus than the na€ıve mice (Fig. 1b).
Next, to try to improve protective immunity, we
immunized mice sequentially with a single dose of DEC-
targeted gag protein vaccine followed by an intranasal boost
with rNDV-L-gag 4 weeks later. Twelve weeks after boosting,
mice were challenged with a recombinant vaccinia gag,
where upon weight loss was monitored daily and lung virus
titers determined as described in the Section Vaccinia-gag
protection assay. All mice lost weight during the first three
days post challenge. However mice receiving either DEC-
empty or rNDV-L-gfp (control vaccines without gag)
showed continuous weight loss. A single dose of rNDV-L-
gag vaccine did not protect against weight loss (Fig. 1a).Mice
receiving two doses of either DEC-gag or rNDV-L-gag
exhibited some protection against weight loss. However,
priming with DEC-gag plus polyICLC protein vaccine
followed by a rNDV-L-gag boost provided superior
protection against weight loss to either two rNDV-L-gag
or DEC-gag vaccines (Fig. 1a) and reduced lung virus titers
by an average of 5 logs in 4 experiments (Fig. 1b), which
titers were significantly lower than mice receiving a
homologous prime boost vaccine (p< 0.02). The control
for the challenge experiment were three viruses including
wild type vaccinia virus with no insert (Vaccinia WT),
recombinant vaccinia-luciferase and recombinant Vaccinia-
OVA (Figure S1).
CD4þ and CD8þ T cells protect mice after DEC-gag
protein-prime rNDV-L-gag-boost vaccine
Female CxB6 F1 Mice vaccinated as indicated in the x-axis of
Figure 2were treatedeitherwith control rat IgG (a)ordepleting
antibodies to aCD4, aCD8, or both (aCD4&aCD8) at days
3, 2, 1 prior to airway challenge with recombinant
vaccinia-gag virus. Lung virus titer (PFU/lung)was determined
7 days after as previously described [21–26].
Generally a depletion of both CD4þ and CD8þ T cells
abrogated protection completely in all vaccine treated
groups (Fig. 2d). In Figure 2b and c the depletion of
CD8þ T cells after homologous rNDV-L-gag vaccination
resulted to a stronger reduction in protection, that is, a
significant increase (p< 0.05) in lung virus titer (at least 20
fold) compared to CD4þ T cell depletion (threefold
increase). On the other hand as shown in Figure 2b CD4þ
T cell depletion in contrast to CD8 resulted to a 34 fold
increase in lung virus titer. This indicates that protection
arising from rNDV-L-gag vaccination is dominated by
CD8þ T cells in contrast to DEC-gag vaccination which is
dominated as previously reported in our group by CD4þ T
cells. Depletion of CD8þ T cells following complementary
prime boost vaccination resulted to a 500 fold increase in
lung virus titer post challenge as against 62 fold increase
following CD4þ T cell depletion. This implies that superior
protective CD8þ T cells are mobilized after complementary
prime boost (CPB) and play a critical role in controlling the
virus in the air way.
CPB with DC targeted gag protein vaccine and
rNDV-L-gag results to rapid and durable gag
reactive CD8þ T cells in murine airway
We previously demonstrated that pre-programming of
helper CD4þ T cells by dendritic cell targeted HIV gag
protein plus polyICLC (DEC-gag) vaccination helped DNA
vaccines improve the mobilization of protective CD8þ T
cells in murine airway [22]. Since rNDV-L-gag is adminis-
tered via the intranasal route we tested whether DEC-gag
vaccine can also improve rNDV-L-gag induced CD8þ T cell
response in murine airway. Briefly female 6–8 weeks old
CXB6 F1 mice were vaccinated twice at 4 weeks apart as
indicated in Figure 3b. We then asked whether the priming
with DEC-gag vaccine improved CD8þ T cell responses by
examining the rapidity with which gag-specific CD8þ T cells
were mobilized quantitatively to a site of infection. In four
experiments, 30 days after DEC-gag vaccination, we boosted
the mice with rNDV-L-gag i.n. and then examined the site of
Complementary prime boost vaccination in mice L. N. Ngu et al.
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infection, the lungs, as well as the spleen 7 and 50 days later.
Priming with DEC-gagP24 plus polyICLC followed by
boosting with one dose of rNDV-L-gag led to a rapid and
better accumulation of CD8þ T cells to the lung (p¼ 0.05)
within 7 days than a single dose or 2 doses of rNDV-L-gag
vaccine (compares Fig. 3b rows II, III, &V).
Seven days after DEC-gag prime followed by rNDV-L-gag
boost CD8þ T cell immunity in the lungs increased 8.5 fold
relative to 2x rNDV-L-gag vaccination. When monitored
over time the CD8þ T cell responses persisted for well over
50 days increasing over time in both the spleen and lungs
(Fig. 3d and e). When compared with the spleen CD8þ T cell
accumulation in the lungs was at least three fold higher than
the spleen after complementary prime boost vaccination
(compare Fig. 3d and e).
Homologous vaccination with 2x DEC-gagP24 plus poly-
ICLC produced no gag specific CD8þ T cell responses as
previously reported [23]. To establish that the accumulation of
gag-reactive CD8þ T cells in the lungs and spleen was specific to
the vaccine antigenwe next vaccinatedmice twicewithDEC-gag
protein plus polyICLC then boosted with NDV-L-GFP. In the
absence of gag within the rNDV vector no gag specific tetramer
bindingCD8þTcellsweredetectedclearly indicating thatGFPas
an irrelevant antigen has no effect in mobilizing HIV-1 gag
reactiveCD8þTcell.This is also a control to showthat the rNDV
vector on its own is not responsible for the expansion of pre-
existing antigen specific T cells. Thus complementary DEC-gag
prime- rNDV-L-gag boost enables a rapid and durable
mobilization of CD8þ T cells in murine airway.
DC-targeted protein vaccination results to strong
combined CD4þ and CD8þ T cell immunity to an
rNDV-L-gag vaccine
To assess T cell immunity after vaccination with dendritic
cell targeted gag protein followed by a rNDV-L-gag boost, we
measured CD4þ and CD8þ, gag-specific T cells at the single
cell level. One dose of rNDV-L-gag elicited weak CD4þ and
CD8þ immunity (Fig. 4a–d, row II). In Figure 4a–d, rows III
& IV data is shown for homologous vaccination with either
2x rNDV-L-gag or 2x DC targeted protein plus polyICLC.
Whereas vaccination with 2x DEC-gag protein plus
polyICLC resulted to strong CD4þ T cells most of which
were also simultaneously producing IFNg, IL-2 and TNF-a
as previously reported by our group [22–25], immunization
with 2x NDV-L-gag elicited weak CD4þ T Cells (compare
Fig. 4a and b rows III with IV & V) and some CD8þ T cells.
When mice vaccinated twice with DC targeted protein plus
polyICLC are boosted with NDV-L-GFP only CD4þ T cell
specific to the gag protein are detected clearly indicating that
GFP as an irrelevant antigen would not boost preprogramed
gag specific T cells. This is also a control to show that the
NDV vector on its own is not responsible for the expansion
of pre-existing antigen specific T cells. On the other hand
prior vaccination with DC targeted protein resulted in
strong combined CD4þ and CD8þ T cells immunity to a
single dose of NDV-L-gag (Fig. 4a–d, compare rows VI).
Thus complementary prime boost enables a balanced
induction of both CD4þ and CD8þ T cells (Figure S2).
CPB with DC targeted gag protein vaccine and
rNDV-L-gag elicits durable polyfunctional T cells
T cells producing multiple cytokines appear to be especially
effective in protective immunity [9, 28–31] and have been
associated with long term control of HIV-1 in elite
controllers. We therefore examined the quality of the T
cell responses induced by complementary DC targeted
protein and rNDV-L-gag vaccination in terms of the ability
of the gag specific T cells to secretemultiple cytokines such as
Figure 1. Complementary protein prime-rNDV-L-gag boost vaccination
results to a vigorous protection in the airway. CxB6 F1 mice were
vaccinated as indicated in (a) and the x-axis of (b) then challenged
12 weeks after the last boost. In a weight loss was monitored daily for
7 days and lung virus titer determined as previously reported [22, 23, 25,
26]. (b) Mean SD lung virus titers (PFU/ml) of three repeat experiments
are shown (p¼ 0.02, p¼ 0.04, p¼ 0.05, p¼ 0.08 ns, notsigniﬁcant
(two tailed t test).
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IFNg, TNF-a, and IL-2 (polyfunctional T cells) . Briefly
female CxB6 F1mice were vaccinated as described above and
the gag specific T cells were assessed at the single cell level for
their ability to secrete multiple cytokines such as IFNg, TNF-
a, and IL-2 (Fig. 5). In four separate experiments seven days
after immunization complementary DC targeted gag and
rNDV-L-gag vaccination enabled the induction of triple
cytokine secreting cells (including IFNg, IL-2, and TNF-a)
by both CD4 and CD8 T cells (Fig. 5a and b). Particularly in
the CD8þ T cell compartment cytokine formation after CPB
vaccination was significantly higher (p< 0.003) than
immunization with 2x NDV-L-gag.
As previously reported homologous vaccination with 2x
DEC-gag plus polyICLC vaccination resulted to strong
polyfunctional T cell responses only in the CD4þ compart-
ment with no detectable gag specific polyfunctional CD8þ T
Figure 2. CD4þ and CD8þ T cells protectmice after DEC-gag protein-prime rNDV-L-gag-boost vaccine.Mice vaccinated as indicated in x-axis of Figure 3
(a–d) above were treated as indicated with control rat IgG or depleting antibodies to aCD4, aCD8, or both (aCD4 & aCD8) at days3,2,1 prior to
airway challenge with recombinant vaccinia-gag virus. Lung virus titer (PFU/lung) was determined 7 days after challenge with recombinant vaccinia-gag
virus (Mean SD of three repeat experiments) (ns, not signiﬁcant (two tailed student's t test).
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cells [22, 23, 25]. As shown in Figure 5a more double
cytokine forming cells were also detected in gag specific
CD4þ T cells than in the CD8 compartment. When
monitored 50d later multiple cytokine forming cells
persisted in both the CD4þ and CD8þ compartment
(Fig. 5c and d). Thus CPB provides improved systemic
CD4þ and CD8þ T cell immunity to one dose of rNDV-L-
gag vaccine.
Figure 3. Complementary DEC-gag protein prime rNDV-L-gag boost vaccine allows for enhanced accumulation of CD8þ T cells to an infection
challenge site. CxB6F1 mice vaccinated as described in Figures 3, 4 were assessed for tetramer binding CD8þ T cells in the spleen and the lungs as the
infection site. HIV gag speciﬁc CD8þ T cells were enumerated by binding of tetramers formed from H-2Kd and HIV gag peptide (AMQMLKETI). (a) FACS
data to illustrate gating schema for tetramer binding CD8þ T cells in lungs and spleen 10d after rNDV-Lgag boost vaccine. (b) As in (a) Female CXB6 F1
mice were vaccinated as indicated in the y-axis and 10 days lungs are dissociated to determine tetramer binding cells. (c) as in (a) but mean SD of three
experiments. (d) as in (b) but 50 days after the rNDV-L-gag boost (p¼ 0.05 student's t test). (e) as in (c) mean SD of three experiments 50 days after
rNDV-L-gag boost.
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Figure 4. Complementary DEC-gag protein prime rNDV-L-gag boost vaccination induces robust balanced CD4þ and CD8þ T cell immunity. Female
CxB6 F1 mice were vaccinated as shown in the y-axis of Figure 3, 7–10 days after the rNDV-L-gag boost, bulk splenocytes were assessed for T cell
immunity. Splenocytes were restimulated either with unreactive peptides or with an HIV gagP24 peptide mix, and cytokine production (IFN-g, IL-2, and
TNF-a) in response to peptide was evaluated by intracellular cytokine staining 6h later in CD4þ (a and b) or CD8þ (c and d), CD3þ T cells. In Figure 3 total
IFNg production is shown for CD4þ (a) or CD8þ (c) T cells; whereas in b and c multiple cytokine forming cells are displayed for CD4þ and CD8þ T cells
respectively.
Complementary prime boost vaccination in mice L. N. Ngu et al.
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Figure 5. Complementary DEC-gag protein prime rNDV-L-gag boost vaccination induces robust and durable polyfunctional CD4þand CD8þ T cell
immunity. Female CXB6 F1 mice were vaccinated and T cell immunity measured as described in Figure 4. Cytokine production proﬁle of single cells is
assessed as shown in the gating schema in Figure 4a. Seven days after the rNDV-L-gag vaccine boost CD4þ (b) and CD8þ (c) T cells produce multiple
cytokines including various combinations of IFN-g, IL-2, and TNF-a. Fifty days after the rNDV-L-gag vaccine boost, we again measured HIV-1 gag speciﬁc
cytokine production combinations in single CD4þ (d) and CD8þ (e) T cells, All data are mean SD of 3 experiments involving 5 F1 mice per group.
L. N. Ngu et al. Complementary prime boost vaccination in mice
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Discussion
In this study, we demonstrate that successive administration
of DEC-gag protein and rNDV-L-gag vaccines results to
vigorous systemic and mucosal T cell immunity. Here
antigen specific helper CD4þ T cells are elicited by a priming
dose of a DEC-targeted protein vaccine which then improves
the induction of T cell immunity in murine airway by an
rNDV-L-gag vaccine. In addition to an enhanced T cell
immunity; this approach strongly amplified persistent
polyfunctional T cells in the vaccinees and improved
protection against airway challenge with a recombinant
vaccinia gag virus. To the best of our knowledge, this is the
first viral vectored vaccine strategy in mice where by the
concept of helper CD4þ T cells has been exploited not only
to direct the induction of a balancedHIV-1 gag specific T cell
immunity but equally to intentionally focus broadly reactive
T cell responses at the site of pathogenic virus challenge.
This approach as previously reported in our group for
DNA vaccines [22] is termed complementary prime boost
vaccination because two vaccines inducing different types of
immunity are combined together to achieve effective
immunization. This concept is now extended here to
include directing mucosal viral vectored vaccine with helper
CD4þ T cells to focus T cell immunity at pathogenic virus
entry points. However unlike our previous report where
initially the was lesser vaccine specific T cells in the lungs vis a
vis spleen [22, 32] following complementary DEC-gag
prime-rNDV-L-gag vaccine boost at least 3 to 8 fold more
long lasting tetramer binding CD8þT cells are induced in the
lungs than the spleen. In the context of HIV-1 infection
robust multifunctional mucosal T cells would be vital not
only in abrogating infection but equally in limiting HIV-1
viral reservoirs establishment through active killing of virus
producing cells [7, 8, 33–35]. Multiple vaccine combination
strategies have been exploited to augment viral vectored
vaccines mediated T cell immunity (reviewed in
Ref. [36–41]), including heterologous vector prime protein
boost or vice versa [42–44].
However in CPB we emphasize combining dendritic cell
targeted antigen vaccination with other conventional ap-
proaches because it intensifies and broadens antigen specific
immune responses [22, 23, 45–50]. Here coordinated cellular
interplay between DC, CD4, CD8, B, and probably other
immune cells is critical not only in shaping the quantity or
quality of the vaccinemediated immune responses but also in
the ultimate protection from pathogenic viral challenge.
Synthetic double-stranded RNA, polyICLC, for example, is
necessary to activate DC loaded with HIV-1 gag to induce
broadly reactive helperCD4þT cells as previously reported in
our group [22, 23, 25, 49, 51]. During this process IFNAR
signaling in DC after polyICLC stimulation has recently been
demonstrated [51] to be a pre-requisite for the effective
induction of CD4þ and CD8þ T cells. In addition evidence
also indicates that this signaling activates all path ways
necessary for immune induction and also reprograms DC
metabolism for effective immune induction [50, 52]. On the
other hand the contribution of CD4þ T cells to the CPB
strategy are numerous including our previous report [22] and
several other findings demonstrating the usefulness of helper
CD4þ T cells in T cell immunity [22, 32, 43] (reviewed in
Ref. [53, 54]).
The complementary prime boost approach described
here, in which DC-targeted protein vaccine favors helper cell
formation and rNDV-L-gag vaccine favors mucosal T cell
immunity limits repeated vector administration thereby
reducing anti-vector immunity as well as competition
between peptides presented from vector and vaccine
antigens. By directing the helper response to defined
proteins, it may be feasible to amplify and improve the
quality of the immunity induced by viral vectored vaccines,
and augment resistance to infectious andmalignant diseases.
Nevertheless there is a need to assess the efficacy of this
strategy in nonhuman primate models and subsequently in
first in clinical trials.
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Figure S1. Protection following complementary DEC-gag
protein prime-rNDV-L-gag boost is HIV Gag dependent.
Figure S2. Complementary protein prime-rNDV-L gag
boost vaccination induces equitable CD4 and CD8 T cell
immunity.
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